Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Veru (VERU)
NASDAQ:VERU
Veru (VERU) Stock Price & Analysis
1,456 Followers
VERU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.34 - $24.55
Previous Close$5.76
Volume1.24M
Average Volume (3M)4.26M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$80.19M
Total Debt (Recent Filing)$15.88M
Price to Earnings (P/E)-5.5
Beta-2.55
Next EarningsFeb 09, 2023
EPS Estimate-$0.38
Last Dividend Ex-DateApr 28, 2014
Dividend YieldN/A
1Y Price Target$17.50
EPS (TTM)-1.04
Shares Outstanding80,623,128
R-Squared0.00151
Standard Deviation0.35
10 Day Avg. Volume1,788,629
30 Day Avg. Volume4,258,482
Price to Book (P/B)6.64
Price to Sales (P/S)18.86
Price to Cash Flow (P/CF)528.30
P/FCF Ratio-12.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside203.82% Upside
Rating ConsensusModerate Buy
Alpha0.07
Number of Analyst Covering4
Veru News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERU FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was $4.34 and its highest was $24.55 in the past 12 months.
What is Veru’s market cap?
Currently, no data Available
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is Feb 09, 2023 which is in 4 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Dec 05, 2022. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.302 by -$0.208.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Undervalued.
Does Veru pay dividends?
Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here
What is Veru’s EPS estimate?
Veru’s EPS estimate is -$0.38.
How many shares outstanding does Veru have?
Veru has 80,623,130 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.302. Following the earnings report the stock price went up 5.818%.
Which hedge fund is a major shareholder of Veru?
Among the largest hedge funds holding Veru’s share is Perceptive Advisors LLC. It holds Veru’s shares valued at 45M.
---
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50
$17.50
Blogger Sentiment
Bullish
VERU Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 8.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.19%
12-Months-Change
Fundamentals
Return on Equity
-71.87%
Trailing 12-Months
Asset Growth
-23.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veru
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
---
---